← Back to Clinical Trials
Recruiting Phase 4 NCT07387536

NCT07387536 The Effectiveness of Topical Silicone Application Combined With Photoprotection in the Development of Scarring Following Blepharoplasty

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07387536
Status Recruiting
Phase Phase 4
Sponsor Instituto de Oftalmología Fundación Conde de Valenciana
Condition Scar Formation
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2025-10-01
Primary Completion 2026-03-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Silicone-based topical formulation with sunscreen (SPF 50) application

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.

This trial targets 30 participants in total. It began in 2025-10-01 with a primary completion date of 2026-03-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Assess the efficacy of utilizing topical silicone with photoprotection (Improscar Stick® 50) on the quality of healing following upper blepharoplasty, employing the Vancouver and POSAS scales (both patient and observer) over a minimum follow-up period of three months.

Eligibility Criteria

Inclusion Criteria: * The study participants are individuals aged 18 years and older, encompassing both male and female subjects. These participants are undergoing blepharoplasty and have provided their written informed consent to partake in the research. Exclusion Criteria: * Individuals with a history of previous surgical procedures on the eyelids, apart from the current blepharoplasty. . Those who have previously undergone intralesional modulation are also considered. Individuals with a known allergy to any components of the product under investigation. The presence of local skin infections in the treatment area. Suspicious skin lesions suggestive of malignancy in the eyelid region. Pregnancy or breastfeeding during the study. - Research subjects who, after being included in the study, do not complete the scheduled clinical follow-up. Research subjects who discontinue the use of the topical treatment before the end of the established period. Voluntary withdrawal of informed consent at any stage of the study. Later detection of exclusion criteria that were not identified during the initial evaluation.

Contact & Investigator

Central Contact

Kathia Gutierrez Juarez MD, Medical Doctor

✉ katgtzouu@gmail.com

📞 +52 55 2719 3333

Frequently Asked Questions

Who can join the NCT07387536 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Scar Formation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

What phase is the NCT07387536 trial and what does that mean for participants?

Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.

Is NCT07387536 currently recruiting?

Yes, NCT07387536 is actively recruiting participants. Contact the research team at katgtzouu@gmail.com for enrollment information.

Where is the NCT07387536 trial being conducted?

This trial is being conducted at Mexico City, Mexico.

Who is sponsoring the NCT07387536 clinical trial?

NCT07387536 is sponsored by Instituto de Oftalmología Fundación Conde de Valenciana. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology